Full Text of PDF (455k)
Article in Japanese
Abstract
Case Report
Re-exacerbation of immune-related lung injury following transient improvement with infliximab
Itaru Ohsawaa Shojiroh Morinagab Mamoru Sasakia Tomoo Kakimotoa Takashi Shimadaa Naoto Minematsua
aDepartment of Internal Medicine, Hino Municipal Hospital
bDepartment of Diagnostic Pathology, Hino Municipal Hospital
ABSTRACT
A 70-year-old male experienced immune-related lung injury that was refractory to corticosteroid therapy following administration of pembrolizumab as first-line treatment for non-small cell lung cancer. The lung injury transiently improved following treatment with infliximab but worsened two weeks later, leading to lethal respiratory failure. An autopsy revealed organizing and acute phases of diffuse alveolar damage, which presumably reflected the primary lung injury and its re-exacerbation, respectively. The withdrawal of infliximab might be associated with the re-exacerbation of the lung injury. The present case suggests that the administration of infliximab for recurrent immune-related lung injury should be considered.
KEYWORDS
Lung cancer Immune-related adverse event Lung injury Immune checkpoint inhibitor (ICI) Infliximab (IFX)
Received 1 Sep 2020 ／ Accepted 22 Oct 2020
AJRS, 10(2): 139-143, 2021
Copyright © The Japanese Respiratory Society All Rights Reserved.